- Details
- Ashish Kamat introduces Stephen B. Williams who discusses findings from his study on blue light cystoscopy in bladder cancer treatment, conducted within the VA healthcare system. The study utilized a propensity score-matched analysis to compare the outcomes of blue light versus white light cystoscopy, focusing on bladder cancer recurrence, progression, and overall survival. The analysis revealed s...
|
- Details
- Ashish Kamat hosts Sam Chang to discuss the SunRISe-3 trial. Dr. Chang presents the ongoing trial investigating the efficacy of TAR-200, either alone or combined with cetrelimab, against BCG in treating patients with BCG-naive bladder cancer. TAR-200, a targeted release system using gemcitabine, is tested for its potential benefits over traditional treatments due to its unique delivery system aime...
|
- Details
- Ashish Kamat welcomes Siamak (Sia) Daneshmand to discuss the nuances of blue light cystoscopy and its effectiveness across different racial groups. Dr. Daneshmand discusses his team’s research into racial differences in tumor detection rates using blue light cystoscopy. He highlights the study's analysis of detection sensitivity across different races, revealing that while blue light enhances tumo...
|
- Details
- Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association's (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in partnership with the Society for Urologic Oncology, these evidence-based guidelines highlight key changes from the 2016 and 2017 versions. The updates include the management of variant histologies, re...
|
- Details
- Sam Chang introduces a dialogue with John Gore and Angie Smith, who are leading a trial named CISTO, aimed at addressing treatment decisions in non-muscle invasive bladder cancer. The trial compares the efficacy of intravesical therapy and surgery in patients with recurrent bladder cancer who have previously undergone BCG treatment. Emphasizing a pragmatic approach, the trial notably includes phys...
|
- Details
- Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November 2023....
|
- Details
- Ruchika Talwar hosts Marshall Strother for a discussion on the recovery timeline following TURBT for bladder cancer. Utilizing ecological momentary assessment, Dr. Strother's study tracks patient symptoms and recovery in real-time through daily text-based surveys, offering a detailed view of the recovery process. Findings reveal most patients experience mild symptoms post-surgery, with a significa...
|
- Details
- Ruchika Talwar hosts Hannah Kay and Marc Bjurlin to unravel their study on the sparse reporting of smoking status in bladder cancer trials. Their research, "Clearing the Smoke," highlights a concerning discrepancy: only 41.2% of bladder cancer trials over the past decade reported participants' smoking status, starkly contrasting with higher reporting rates in lung cancer trials. This gap suggests...
|
- Details
- Sam Chang engages in an conversation with Elizabeth Koehne who delves into her research, AIM HIGH: DNA Methyltransferase Inhibition and Immune Stimulation in Bladder Cancer. The project explores the potential of making bladder cancer more susceptible to immunotherapy by reversing epigenetic mechanisms, like DNA methylation and chromatin remodeling, that the cancer uses to evade the immune system....
|
- Details
- Sam Chang hosts a conversation with Vignesh Packiam to discuss the emerging role of intravesical gemcitabine and docetaxel (gem/doce) for treating non-muscle invasive bladder cancer (NMIBC), spotlighting Dr. Packiam's recent publication in Urologic Oncology. The study, a retrospective review focusing on AUA intermediate-risk NMIBC patients, demonstrates the regimen's efficacy and tolerability. It...
|
